Literature DB >> 16543548

Levetiracetam can be effective in the treatment of restless legs syndrome with periodic limb movements in sleep: report of two cases.

G Della Marca, C Vollono, P Mariotti, M Mazza, G F Mennuni, P Tonali, S Mazza.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16543548      PMCID： PMC2077523          DOI： 10.1136/jnnp.2005.075671

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  5 in total

1.  Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.

Authors:  Theresa A Zesiewicz; Kelly L Sullivan; John L Maldonado; William O Tatum; Robert A Hauser
Journal:  Mov Disord       Date:  2005-09       Impact factor: 10.338

2.  Specific effect of levetiracetam in experimental human pain models.

Authors:  Thomas P Enggaard; Niels A Klitgaard; Søren H Sindrup
Journal:  Eur J Pain       Date:  2005-06-08       Impact factor: 3.931

Review 3.  Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health.

Authors:  Richard P Allen; Daniel Picchietti; Wayne A Hening; Claudia Trenkwalder; Arthur S Walters; Jacques Montplaisi
Journal:  Sleep Med       Date:  2003-03       Impact factor: 3.492

Review 4.  Restless legs syndrome: an update on treatment options.

Authors:  Anthony H V Schapira
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.

Authors:  Berkley A Lynch; Nathalie Lambeng; Karl Nocka; Patricia Kensel-Hammes; Sandra M Bajjalieh; Alain Matagne; Bruno Fuks
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205
  5 in total
  3 in total

1.  Treatment options for sleep dysfunction in Parkinson's disease.

Authors:  Mary Ann Thenganatt; Steven J Frucht
Journal:  Curr Treat Options Neurol       Date:  2011-10       Impact factor: 3.598

2.  Treatment Options in Intractable Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED).

Authors:  Fabrizio Rinaldi; Andrea Galbiati; Sara Marelli; Luigi Ferini Strambi; Marco Zucconi
Journal:  Curr Treat Options Neurol       Date:  2016-02       Impact factor: 3.598

Review 3.  Strategies for the treatment of restless legs syndrome.

Authors:  Mark J Buchfuhrer
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.